Novartis wins landmark approval for a biosimilar of Amgen's Neupogen

March 6, 2015 4:25 PM

11 0

Novartis ($NVS) will be the first to hit U.S. shores with a copy of a blockbuster biotech drug, winning FDA approval for its take on Amgen's ($AMGN) Neupogen and heralding a new era in biopharma.

The injection, to be sold as Zarxio, is designed to boost white blood cell counts and is commonly used to ease the side effects of chemo- and cell therapy. The FDA has cleared Novartis' version for all 5 of Neupogen's approved indications, giving the Swiss drugmaker a chance to cut in on the roughly...

Also read: From the Pulpit: Is Aaron Hernandez in heaven?

Read more

To category page